SELLAS Life Sciences Group Quarterly Cash Flow Statement
NASDAQ: SLSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
11.65+0.39 (+3.46%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
SELLAS Life Sciences Group free cash flow
In the quarter ended Jun 30, 2026, SELLAS Life Sciences Group generated -$7.6 million of operating cash flow. That left free cash flow of -$7.6 million.
Summary generated from market data by MetaCap's automated system. Methodology
SELLAS Life Sciences Group cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -9.61M | -8.41M | -7.66M | -6.79M | -6.60M | -5.81M | -6.74M | -7.11M | -7.47M | -9.57M | -8.14M | -9.27M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | 1.01M | 798.00K | 447.00K | 503.00K | 501.00K | 505.00K | 373.00K | 381.00K | 334.00K | 476.00K | 497.00K | 543.00K |
| Change in Working Capital | 1.01M | -1.23M | 2.29M | -769.00K | -1.22M | -3.75M | -802.00K | -1.08M | -2.55M | -1.68M | 2.82M | 1.84M |
| Operating Cash Flow | -7.59M | -8.85M | -4.92M | -7.07M | -7.33M | -9.07M | -7.15M | -7.81M | -9.68M | -10.76M | -4.83M | -6.89M |
| Investing Cash Flow | — | — | — | — | — | — | 0 | 0 | — | — | 0 | -3.00M |
| Financing Cash Flow | 38.83M | 44.15M | 32.39M | 26.09M | 4.23M | 23.58M | 8.00K | 19.69M | 414.00K | 26.65M | 3.39M | 54.00K |
| Net Change in Cash | 31.25M | 35.30M | 27.47M | 19.02M | -3.10M | 14.51M | -7.14M | 11.88M | -9.27M | 15.88M | -1.44M | -9.84M |
| Free Cash Flow | -7.59M | -8.85M | -4.92M | -7.07M | -7.33M | -9.07M | -7.15M | -7.81M | -9.68M | -10.76M | -4.83M | -6.89M |
This table shows 12 quarterly periods of SELLAS Life Sciences Group's cash flow statement, from Q2 2026 back to Q3 2023, across 14 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow SLS's reporting calendar. What is a cash flow statement?